Apr 24 |
Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus
|
Apr 24 |
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
|
Apr 23 |
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
|
Apr 23 |
Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?
|
Apr 22 |
Undervalued Icons: 3 Household Names Trading at Steep Discounts
|
Apr 22 |
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
|
Apr 22 |
Gilead Sciences: Some Signs Of An Impending Bottom
|
Apr 22 |
Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics
|
Apr 21 |
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
|
Apr 19 |
FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk
|